Innovative Food Holdings Inc (IVFH): The split can’t be very big with the cur...

jimr1717 · 2024-12-05T23:11:21.6570000Z

The split can’t be very big with the current OS. Don’t understand the need.

Play Episode

7min

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Proactive - Interviews for investors

HIVE Digital reports 89 BTC mined in February, plans 4x hashrate expansion by September 2025

Hive Digital Technologies Executive Chairman Frank Holmes joined Steve Darling from Proactive to discuss the company’s unaudited Bitcoin production results for February 2025. HIVE mined 89 BTC during the month, bringing its total Bitcoin holdings to 2,620 BTC, valued at approximately $220 million as of February 28, based on a BTC price of $84,000. Holmes highlighted that HIVE's Bitcoin holdings have grown by 23% year-over-year. However, on a month-over-month basis, BTC reserves declined as the company strategically sold a portion of its holdings to reinvest in capital assets, including acquiring Bitfarms’ 200 MW hydro-powered Bitcoin mining facilities in Paraguay. Despite the asset reallocation, HIVE maintained a strong mining capacity, averaging 5.6 Exahash per Second (EH/s) with fleet efficiency at 20.9 Joules per Terahash. The company achieved a peak BTC-only hashrate of 6.2 EH/s and a peak BTC-equivalent hashrate of 6.4 EH/s, with an average daily production rate of 3.2 BTC—equivalent to 16 BTC per Exahash. Looking ahead, HIVE is targeting significant growth in 2025, with plans to quadruple its hashrate from 6 EH/s to 25 EH/s by September. The company’s 300 MW expansion in Paraguay is a key part of this strategy, with phased energization of miners set for calendar Q2 2025. The first 100 MW will be deployed at Yguazú, followed by another 100 MW at Valenzuela, positioning HIVE for substantial scale-up in the competitive Bitcoin mining landscape. #proactiveinvestors #hivedigitaltechnologieslet #tsxv #hive #nasdaq #hive

Proactive - Interviews for investors

KEFI Gold and Copper gets green light to progress with Tulu Kapi project in Ethiopia

KEFI Gold and Copper PLC executive chairman Harry Anagnostaras-Adams talked with Proactive about a major milestone for the company’s flagship Tulu Kapi gold project in Ethiopia. He described the latest announcement as the most significant since KEFI decided to focus on the Arabian Nubian Shield in 2008. Anagnostaras-Adams confirmed that all stakeholders in the project have now given the green light, marking the start of the next phase. He emphasised that there is no risk of being blocked, as land resettlement is progressing with the support of the local community. The process, involving thousands of people, is expected to be completed within a month, alongside final project preparations. He reiterated that the company has passed the “point of no return” and is now expediting the project’s launch. Investors seeking more details on KEFI’s technical, environmental, and financial studies can find extensive information on the company’s website: https://www.kefi-goldandcopper.com For more updates on KEFI Gold and Copper and other industry developments, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for the latest insights. Relevant Hashtags #KEFIGold #GoldMining #CopperMining #TuluKapi #EthiopiaMining #MiningInvestment #GoldStocks #ResourceSector #MiningUpdates #ProactiveInvestors

Proactive - Interviews for investors

Lisata Therapeutics expands drug discovery with GATC AI collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Followers	80
Posts	27028
Boards Moderated	3
Alias Born	10/11/2011

Volume:	137,654
Day Range:	1.84 - 2.05
Bid:	1.90
Ask:	1.97
Last Trade Time:	3:52:24 PM EDT
Total Trades:	172

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

IVFH Detailed Quote

Recent IVFH News

More IVFH News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent IVFH News

Go Ad-Free